Document Detail


Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
MedLine Citation:
PMID:  15097955     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The immune system plays a critical role in the development and pathogenesis of actinic keratosis (AK). Imiquimod has been shown to stimulate the cutaneous immune response and be effective for the treatment of nonmelanoma skin cancers. OBJECTIVE: Two phase III, randomized, double-blind, vehicle-controlled studies evaluated the efficacy of imiquimod 5% cream compared with vehicle in the treatment of AK lesions on the face and balding scalp. METHODS: A total of 436 participants at 24 centers in the United States and Canada were randomized to either imiquimod 5% or vehicle cream. Study cream was applied one time per day, 2 days per week for 16 weeks. Clearance of AK lesions was clinically assessed at an 8-week posttreatment visit. RESULTS: The complete clearance rate was 45.1% for the imiquimod group and 3.2% for the vehicle group. The difference in complete clearance rates (imiquimod minus vehicle) was 41.9% with a 95% confidence interval of 34.9% to 49%. The partial (> or =75%) clearance rate was 59.1% for the imiquimod group and 11.8% for the vehicle group. The difference in partial clearance rates (imiquimod minus vehicle) was 47.3% with a 95% confidence interval of 39.5% to 55.1%. The median percent reduction in AK lesions was 83.3% for the imiquimod group and 0% for the vehicle group. Local skin reactions were common. Severe erythema was reported by 17.7% of participants who received imiquimod and 2.3% of participants who received vehicle. Overall, imiquimod was very well tolerated. CONCLUSION: Imiquimod 5% cream used 2 times per week for 16 weeks is an effective and well-tolerated treatment for AK.
Authors:
Mark Lebwohl; Scott Dinehart; David Whiting; Peter K Lee; Naji Tawfik; Joseph Jorizzo; James H Lee; Terry L Fox
Related Documents :
6191495 - Assay of comedolytic activity in acne patients.
22431145 - One-year results of vital pulp therapy in permanent molars with irreversible pulpitis: ...
16488335 - Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an int...
19120765 - Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. an open lab...
23334785 - The effect of 810-nm low-level laser therapy on pain caused by orthodontic elastomeric ...
9079185 - Septic arthritis after arthroscopic anterior cruciate ligament reconstruction. diagnosi...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  50     ISSN:  0190-9622     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-04-20     Completed Date:  2004-06-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  714-21     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029-6574, USA. Lebwohl@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / administration & dosage*,  adverse effects
Adult
Aged
Aged, 80 and over
Aminoquinolines / administration & dosage*,  adverse effects
Double-Blind Method
Female
Humans
Keratosis / drug therapy*,  etiology
Male
Middle Aged
Ointments
Photosensitivity Disorders / drug therapy*
Ultraviolet Rays / adverse effects*
Vehicles
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Aminoquinolines; 0/Ointments; 0/Vehicles; 99011-02-6/imiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sunless tanning.
Next Document:  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III...